Surgery – Diagnostic testing – Measuring or detecting nonradioactive constituent of body...
Patent
1996-04-29
2000-05-16
Nasser, Robert L.
Surgery
Diagnostic testing
Measuring or detecting nonradioactive constituent of body...
600362, 600573, 600584, A61B 500
Patent
active
060630299
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a diagnostic patch which has various functions and is suitably used particularly for the diagnosis of mammary cancer or atopic dermatitis, and a method for the diagnosis of mammary cancer or atopic dermatitis with said patch.
BACKGROUND OF THE PRIOR ART
Various methods have been employed in the checkup or diagnosis of diseases. For example, biochemical or biological examination is carried out by collecting blood invasively and conducting diagnosis based on the components, diagnostic markers and cells contained in the blood; pathological examination is conducted by conducting the biopsy of cancer tissue or the examination for abnormality on cellular level invasively; and the examination of urine, stool or saliva involves the collection thereof. In carrying out these method, a doctor, nurse or clinical analyst must collect blood with a syringe, must extirpate a tissue (affected site) from a living body with a sharp-edged knife or must collect an object of examination or diagnosis in a special case in cooperation with a patient.
In particular, mammary cancer is known to be a cancer which is difficult to find in an early stage, though it is one of the major cancers which tend to increase. Although the diagnosis of mammary cancer is conducted by internal examination, palpation, mammography (X ray), detection of tumor markers [such as carcinoembryonic antigen (CEA), .alpha.-fetoprotein (AFP), cancer antigen (CA15-3) and various saccharide antigens], ultrasonography or the like, these methods do not always exhibit a high diagnosis efficiency. For example, a phyma-free cancer gives neither pain nor subjective symptoms in early stages, so that patients therewith cannot find abnormality in many cases. Meanwhile the diagnosis based on a tumor marker such as CEA, CA15-3 or AFP is conducted by determining the concentration thereof in blood by radioimmunoassay (RIA) or enzyme immunoassay (EIA) and the concentration of such a tumor marker in blood serves as an indication of the prognosis or therapy effect of a cancer which is advanced considerably or metastasizing to the lymph node. However, it is very difficult to conduct the early diagnosis of primary mammary cancer by determining the concentration, because the positive rate for an early cancer is extremely low.
There were therefore many cases wherein the cancer had been advanced or had metastasized to the lymph node with the result of unwilling mastectomy.
Accordingly, the early diagnosis of mammary cancer is little conducted by the assay of concentration of a tumor marker in blood, but depends on palpation or inquiry. Further, the diagnosis with X ray (such as mammography) involves the exposure of a living body to a considerably high dose of X ray and the reading of a mammograph necessitates much experience and high skill. Further, cytodiagnosis involves the determination of a questionable site. However, it is difficult to find an extremely small affected site by current methods easily and simply.
The assay of specific substances contained in a serum, blood or biopsy specimen is generally conducted by a physiochemical or biochemical method, immuno-assay, a pathological method or the like. Therefore, the assay cannot be conducted at the site of medical services, so that the above specimen must be entrusted to an institution fitted with examination equipment or a special laboratory technician. Accordingly, it takes many days to know the result of the assay, which is problematic particularly in cases necessitating immediate treatment.
On the other hand, atopic dermatitis is steadily increasing owing to change in the living environment, lowering in the adaptation of a living body and lowering in the natural immunity, becoming a socially significant problem. In particular, atopic diseases are extremely prevalent, so that it is said that there are one or two (latent) patients therewith per ten persons in Japan. However, the cause of the diseases has not sufficiently been elucidated as yet and the diagnosis and therapy of
REFERENCES:
patent: 4788971 (1988-12-01), Quisno
patent: 4836217 (1989-06-01), Fischer
patent: 5203327 (1993-04-01), Schoendorfer et al.
patent: 5219762 (1993-06-01), Katamine et al.
Imayama Shuhei
Mukai Mizue
Ohta Shigeo
Okayama Akira
Saita Masaru
Carter Ryan
Hisamitsu Pharmaceutical Co. Inc.
Nasser Robert L.
LandOfFree
Diagnostic patch and method for diagnosis using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic patch and method for diagnosis using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic patch and method for diagnosis using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-254551